US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MetaVia Inc

1.25

+0.05214.34%

Volume:28.08K

Turnover:34.98K

Market Cap:6.37M

PE:-0.17

High:1.28

Open:1.21

Low:1.21

Close:1.20

52wk High:23.10

52wk Low:1.17

Shares:5.09M

Float Shares:3.31M

Volume Ratio:0.94

T/O Rate:0.85%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-7.3500

EPS(LYR):-39.1268

ROE:-195.61%

ROA:-62.58%

PB:1.20

PE(LYR):-0.03

Loading ...

Overview Company News Filings

MetaVia Is Maintained at Buy by HC Wainwright & Co.

MetaVia publishes investor presentation; outlines obesity and MASH pipeline, cash and cash equivalents $10.3 million as of Dec. 31, 2025

MetaVia Inc reports results for the quarter ended December 31 - Earnings Summary

BRIEF-Metavia Reports Year End 2025 Financial Results And Provides Corporate Update

MetaVia Q4 EPS $(0.42) Beats $(1.73) Estimate

MetaVia FY2025 net loss narrows 53% to $13 million; R&D expenses drop 68% to $7 million

Press Release: MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

ADVISORY-Alert wrongly tagged to Metavia Inc withdrawn

MetaVia Inc expected to post a loss of $1.24 a share - Earnings Preview

BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies

BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist

BRIEF-Metavia Advances Glp-1-Based Obesity Program With Irb Approval For Higher-Dose Phase 1 Studies Of Da-1726, A Glp-1 And Glucagon Dual Agonist Demonstrating Best-In-Class Potential For Weight Loss And Glucose Control

MetaVia wins IRB approval for Phase 1 Part 3 trial of DA-1726 in obesity

Metavia Advances Glp-1-Based Obesity Program With Irb Approval for Higher-Dose Phase 1 Studies of Da-1726, a Glp-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

THOMSON REUTERS

MetaVia Inc expected to post a loss of $1.24 a share - Earnings Preview

MetaVia expands vanoglipel patent portfolio protection into 2035

MetaVia CEO Hyung Heon Kim to Join Life Sciences Virtual Investor Forum Fireside Chat

MetaVia Inc. Publishes Investor Presentation on Obesity and MASH Drug Pipeline

MetaVia Showcases Novel Obesity and Metabolic Therapies at Emerging Growth Conference

BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Mohawk,

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MTVA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MTVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":1.2521,"timestamp":1775057884306,"preClose":1.2,"halted":0,"volume":28079,"delay":0,"changeRate":0.0434166666666667,"floatShares":3313200,"shares":5090936,"eps":-7.349999,"marketStatus":"Trading","change":0.0521,"latestTime":"04-01 11:42:05 EDT","open":1.21,"high":1.2799,"low":1.21,"amount":34978.7600093,"amplitude":0.05825,"askPrice":1.26,"askSize":3029,"bidPrice":1.2,"bidSize":2280,"shortable":3,"etf":0,"ttmEps":-7.349999,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775073600000},"marketStatusCode":2,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":1.2,"preHourTrading":{"tag":"盘前","latestPrice":1.21,"preClose":1.2,"latestTime":"09:27 EDT","volume":3887,"amount":4753.8845705,"timestamp":1775050049566,"change":0.01,"changeRate":0.008333,"amplitude":0.058333},"postHourTrading":{"tag":"盘后","latestPrice":1.2,"preClose":1.2,"latestTime":"19:59 EDT","volume":1261,"amount":1504.6555,"timestamp":1775001589847,"change":0,"changeRate":0,"amplitude":0.014417},"volumeRatio":0.939201},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","floatShares":3313200,"roa":"-62.58%","roe":"-195.61%","lyrEps":-39.126846,"volumeRatio":0.939201,"shares":5090936,"dividePrice":0,"high":1.2799,"amplitude":0.05825,"preClose":1.2,"low":1.21,"week52Low":1.17,"pbRate":"1.20","week52High":23.1,"institutionHeld":0,"latestPrice":1.2521,"committee":-0.141081,"eps":-7.349999,"divideRate":0,"volume":28079,"delay":0,"ttmEps":-7.349999,"open":1.21,"prevYearClose":8.42,"prevWeekClose":1.22,"prevMonthClose":1.2,"prevQuarterClose":1.2,"fiveDayClose":1.3,"twentyDayClose":1.61,"sixtyDayClose":8.73},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MTVA\",params:#limit:5,,,undefined,":[{"date":"2026-03-26","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":-2.06,"defaultRemindTime":1774512000000,"name":null,"time":"Pre-Market","dateTimestamp":1774497600000,"actualEps":null},{"market":"US","date":"2025-12-05","symbol":"MTVA","defaultRemindTime":1764945000000,"type":"split","dateTimestamp":1764910800000,"forFactor":11,"toFactor":1,"ratio":11},{"market":"US","date":"2025-11-06","symbol":"MTVA","fiscalQuarterEnding":"2025/09","expectedEps":-0.26,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-08-07","symbol":"MTVA","fiscalQuarterEnding":"2025/06","expectedEps":-0.32,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2025-05-14","symbol":"MTVA","fiscalQuarterEnding":"2025/03","expectedEps":-0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.36}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MTVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MTVA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1735617600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MTVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MTVA","date":"2026-03-31","current":-0.163265,"percent":0.76435,"low":-1.962939,"twenty":-1.11845,"median":-0.562326,"eighty":-0.430359,"high":-0.203888,"avg":-0.695994,"sd":0.360292,"marketCap":5956395},"quantilePoints":[{"date":"2024-12-06","current":-0.714557,"twenty":-0.800304,"median":-0.792227,"eighty":-0.751814,"marketCap":19816823},{"date":"2024-12-13","current":-0.716111,"twenty":-0.79347,"median":-0.728538,"eighty":-0.7158,"marketCap":19859903},{"date":"2024-12-20","current":-0.546792,"twenty":-0.767348,"median":-0.716111,"eighty":-0.685354,"marketCap":15164177},{"date":"2024-12-27","current":-0.562326,"twenty":-0.746234,"median":-0.70213,"eighty":-0.556112,"marketCap":15594978},{"date":"2025-01-03","current":-0.655529,"twenty":-0.730091,"median":-0.686597,"eighty":-0.553006,"marketCap":18179781},{"date":"2025-01-10","current":-0.661742,"twenty":-0.733198,"median":-0.686597,"eighty":-0.564811,"marketCap":18352101},{"date":"2025-01-17","current":-0.58718,"twenty":-0.720771,"median":-0.663296,"eighty":-0.577238,"marketCap":16284258},{"date":"2025-01-24","current":-0.602714,"twenty":-0.720771,"median":-0.647762,"eighty":-0.584073,"marketCap":16715059},{"date":"2025-01-31","current":-0.584073,"twenty":-0.717664,"median":-0.630675,"eighty":-0.584073,"marketCap":16198098},{"date":"2025-02-07","current":-0.562326,"twenty":-0.716111,"median":-0.615141,"eighty":-0.562326,"marketCap":15594978},{"date":"2025-02-14","current":-0.512617,"twenty":-0.714557,"median":-0.608927,"eighty":-0.546792,"marketCap":14216416},{"date":"2025-02-21","current":-0.509511,"twenty":-0.704615,"median":-0.602714,"eighty":-0.540578,"marketCap":14130256},{"date":"2025-02-28","current":-0.453589,"twenty":-0.699297,"median":-0.58718,"eighty":-0.518583,"marketCap":12579374},{"date":"2025-03-07","current":-0.487763,"twenty":-0.688995,"median":-0.584073,"eighty":-0.503297,"marketCap":13527135},{"date":"2025-03-14","current":-0.467569,"twenty":-0.681626,"median":-0.568539,"eighty":-0.495468,"marketCap":12967095},{"date":"2025-03-21","current":-0.48401,"twenty":-0.667956,"median":-0.562326,"eighty":-0.487763,"marketCap":13354815},{"date":"2025-03-28","current":-0.48933,"twenty":-0.662363,"median":-0.546792,"eighty":-0.487763,"marketCap":13501595},{"date":"2025-04-04","current":-0.47992,"twenty":-0.656772,"median":-0.540578,"eighty":-0.485083,"marketCap":13241949},{"date":"2025-04-11","current":-0.429732,"twenty":-0.643102,"median":-0.539025,"eighty":-0.482756,"marketCap":11857170},{"date":"2025-04-17","current":-0.23033,"twenty":-0.636267,"median":-0.537471,"eighty":-0.476844,"marketCap":6355270},{"date":"2025-04-25","current":-0.266622,"twenty":-0.631917,"median":-0.512617,"eighty":-0.463425,"marketCap":7356638},{"date":"2025-05-02","current":-0.239019,"twenty":-0.626947,"median":-0.506404,"eighty":-0.454331,"marketCap":6595010},{"date":"2025-05-09","current":-0.222708,"twenty":-0.618869,"median":-0.49874,"eighty":-0.452346,"marketCap":6144956},{"date":"2025-05-16","current":-0.238257,"twenty":-0.615141,"median":-0.497083,"eighty":-0.429105,"marketCap":5848960},{"date":"2025-05-23","current":-0.285534,"twenty":-0.611413,"median":-0.49458,"eighty":-0.263184,"marketCap":7009578},{"date":"2025-05-30","current":-0.543676,"twenty":-0.612655,"median":-0.49689,"eighty":-0.271352,"marketCap":13346706},{"date":"2025-06-06","current":-0.549972,"twenty":-0.608927,"median":-0.497673,"eighty":-0.281282,"marketCap":13501264},{"date":"2025-06-13","current":-0.597709,"twenty":-0.608927,"median":-0.503297,"eighty":-0.294785,"marketCap":14673160},{"date":"2025-06-20","current":-0.557862,"twenty":-0.607995,"median":-0.509511,"eighty":-0.332562,"marketCap":13694949},{"date":"2025-06-27","current":-0.542591,"twenty":-0.603956,"median":-0.515396,"eighty":-0.428478,"marketCap":13320078},{"date":"2025-07-03","current":-0.516978,"twenty":-0.602714,"median":-0.515103,"eighty":-0.429732,"marketCap":12691292},{"date":"2025-07-11","current":-0.572913,"twenty":-0.599701,"median":-0.516978,"eighty":-0.432869,"marketCap":14064436},{"date":"2025-07-18","current":-0.535431,"twenty":-0.597709,"median":-0.518414,"eighty":-0.439456,"marketCap":13144307},{"date":"2025-07-25","current":-0.587857,"twenty":-0.5965,"median":-0.521601,"eighty":-0.450482,"marketCap":14431313},{"date":"2025-08-01","current":-0.482926,"twenty":-0.587857,"median":-0.520838,"eighty":-0.453589,"marketCap":11855342},{"date":"2025-08-08","current":-0.674088,"twenty":-0.587857,"median":-0.518654,"eighty":-0.453589,"marketCap":12464564},{"date":"2025-08-15","current":-0.837521,"twenty":-0.602714,"median":-0.525504,"eighty":-0.453589,"marketCap":15486597},{"date":"2025-08-22","current":-0.836212,"twenty":-0.615141,"median":-0.534692,"eighty":-0.453589,"marketCap":15462399},{"date":"2025-08-29","current":-0.846681,"twenty":-0.624461,"median":-0.53558,"eighty":-0.454826,"marketCap":15655982},{"date":"2025-09-05","current":-0.898895,"twenty":-0.643102,"median":-0.537471,"eighty":-0.457336,"marketCap":16621475},{"date":"2025-09-12","current":-0.894708,"twenty":-0.675347,"median":-0.537746,"eighty":-0.459434,"marketCap":16544042},{"date":"2025-09-19","current":-1.200403,"twenty":-0.704615,"median":-0.540578,"eighty":-0.459802,"marketCap":22196650},{"date":"2025-09-26","current":-1.308626,"twenty":-0.720771,"median":-0.542033,"eighty":-0.464632,"marketCap":24197809},{"date":"2025-10-03","current":-1.285464,"twenty":-0.777314,"median":-0.543184,"eighty":-0.467223,"marketCap":23769507},{"date":"2025-10-10","current":-1.347885,"twenty":-0.814044,"median":-0.546792,"eighty":-0.468812,"marketCap":24923743},{"date":"2025-10-17","current":-1.360971,"twenty":-0.829721,"median":-0.548697,"eighty":-0.471608,"marketCap":25165721},{"date":"2025-10-24","current":-1.257721,"twenty":-0.836474,"median":-0.551486,"eighty":-0.475169,"marketCap":23256514},{"date":"2025-10-31","current":-1.275649,"twenty":-0.839353,"median":-0.556987,"eighty":-0.478202,"marketCap":23588024},{"date":"2025-11-07","current":-1.112332,"twenty":-0.856339,"median":-0.562326,"eighty":-0.479691,"marketCap":20568137},{"date":"2025-11-14","current":-0.985555,"twenty":-0.895545,"median":-0.562464,"eighty":-0.481224,"marketCap":15981760},{"date":"2025-11-21","current":-0.990035,"twenty":-0.925649,"median":-0.572913,"eighty":-0.482587,"marketCap":16054404},{"date":"2025-11-28","current":-1.16176,"twenty":-1.03994,"median":-0.573323,"eighty":-0.482894,"marketCap":18839105},{"date":"2025-12-05","current":-0.993021,"twenty":-1.048481,"median":-0.575956,"eighty":-0.483005,"marketCap":16102829},{"date":"2025-12-12","current":-1.162032,"twenty":-1.114901,"median":-0.581053,"eighty":-0.483057,"marketCap":18843504},{"date":"2025-12-19","current":-1.126736,"twenty":-1.121412,"median":-0.584073,"eighty":-0.483629,"marketCap":18271155},{"date":"2025-12-26","current":-1.324933,"twenty":-1.135751,"median":-0.58567,"eighty":-0.484268,"marketCap":21485117},{"date":"2026-01-02","current":-1.143026,"twenty":-1.158344,"median":-0.587519,"eighty":-0.484763,"marketCap":18535316},{"date":"2026-01-09","current":-1.138004,"twenty":-1.161978,"median":-0.597709,"eighty":-0.485344,"marketCap":18453866},{"date":"2026-01-16","current":-0.447979,"twenty":-1.16176,"median":-0.601208,"eighty":-0.485344,"marketCap":7264435},{"date":"2026-01-23","current":-0.551981,"twenty":-1.16176,"median":-0.598705,"eighty":-0.485958,"marketCap":8950917},{"date":"2026-01-30","current":-0.466908,"twenty":-1.144681,"median":-0.593528,"eighty":-0.48519,"marketCap":7571385},{"date":"2026-02-06","current":-0.342268,"twenty":-1.143026,"median":-0.58718,"eighty":-0.483057,"marketCap":5550210},{"date":"2026-02-13","current":-0.328419,"twenty":-1.140855,"median":-0.584073,"eighty":-0.480757,"marketCap":5325635},{"date":"2026-02-20","current":-0.308634,"twenty":-1.138574,"median":-0.583444,"eighty":-0.475169,"marketCap":5004813},{"date":"2026-02-27","current":-0.31457,"twenty":-1.130076,"median":-0.57751,"eighty":-0.466694,"marketCap":5101060},{"date":"2026-03-06","current":-0.31457,"twenty":-1.127008,"median":-0.573733,"eighty":-0.459434,"marketCap":5101060},{"date":"2026-03-13","current":-0.318526,"twenty":-1.122978,"median":-0.572913,"eighty":-0.453589,"marketCap":5165224},{"date":"2026-03-20","current":-0.292807,"twenty":-1.121203,"median":-0.56645,"eighty":-0.449981,"marketCap":4748156},{"date":"2026-03-27","current":-0.359359,"twenty":-1.119202,"median":-0.562326,"eighty":-0.429418,"marketCap":4661961},{"date":"2026-03-31","current":-0.459138,"twenty":-1.11845,"median":-0.562326,"eighty":-0.430359,"marketCap":5956395}],"updateTime":1775032804343},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MTVA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622879165","title":"MetaVia Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622879165","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622879165?lang=en_us&edition=fundamental","pubTime":"2026-03-28 00:37","pubTimestamp":1774629420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 12:37 ET (16:37 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622994258","title":"MetaVia publishes investor presentation; outlines obesity and MASH pipeline, cash and cash equivalents $10.3 million as of Dec. 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2622994258","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622994258?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:41","pubTimestamp":1774557719,"startTime":"0","endTime":"0","summary":"MetaVia publishes investor presentation; outlines obesity and MASH pipeline, cash and cash equivalents $10.3 million as of Dec. 31, 2025. MetaVia outlined a cardiometabolic pipeline focused on obesity and metabolic dysfunction-associated steatohepatitis , highlighting DA-1726 and vanoglipel .For DA-1726, the company reported -9.1% body weight and -23.7% liver stiffness at Day 54 at a 48 mg dose.MetaVia said DA-1726 Phase 1 Part 3 is evaluating stepwise titration up to 64 mg, with data expected by YE 2026.For vanoglipel, MetaVia said a Phase 2a study in presumed MASH met its primary endpoint and reported ALT reduction of 22.8 U/L.MetaVia reported cash and cash equivalents of USD 10.3 million and no debt as of December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3Ynvsd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622893603","title":"MetaVia Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622893603","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622893603?lang=en_us&edition=fundamental","pubTime":"2026-03-27 02:43","pubTimestamp":1774550592,"startTime":"0","endTime":"0","summary":"MetaVia Inc reports results for the quarter ended December 31 - Earnings SummaryMetaVia Inc MTVA.OQ reported a quarterly adjusted loss of 42 cents per share for the quarter ended December 31, higher t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E289:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850154","title":"BRIEF-Metavia Reports Year End 2025 Financial Results And Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850154","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850154?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:49","pubTimestamp":1774529398,"startTime":"0","endTime":"0","summary":"BRIEF-Metavia Reports Year End 2025 Financial Results And Provides Corporate UpdateMetaVia Inc MTVA.O:METAVIA REPORTS YEAR END 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATESource text: ID:nPnbqN84TaFurther company coverage: MTVA.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA6WLVPB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850898","title":"MetaVia Q4 EPS $(0.42) Beats $(1.73) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850898","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850898?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:37","pubTimestamp":1774528623,"startTime":"0","endTime":"0","summary":"MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(1.73) by 75.69 percent. This is a 88.07 percent increase over losses of $(3.52) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51479543/metavia-q4-eps-0-42-beats-1-73-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622577768","title":"MetaVia FY2025 net loss narrows 53% to $13 million; R&D expenses drop 68% to $7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622577768","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622577768?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:32","pubTimestamp":1774528329,"startTime":"0","endTime":"0","summary":"MetaVia published a press release reporting year-end 2025 financial results and a corporate update.Net loss was USD 13.0 million, or USD 7.35 per share.Operating expenses were USD 13.7 million, down 52.42%.R&D expenses were USD 6.8 million, down 68.45%, primarily due to lower direct development spending on vanoglipel and DA-1726.Cash and cash equivalents were USD 10.3 million, down 35.84%, and management said year-end cash plus proceeds from a January 2026 public offering are expected to fund operations into the fourth quarter of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLbKWp89:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622084857","title":"Press Release: MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622084857","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622084857?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:31","pubTimestamp":1774528260,"startTime":"0","endTime":"0","summary":"48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit. Planned Phase 1 Part 3 16-Week Titration Study to Evaluate 48 mg  and 64 mg  Regimen Receives IRB Approval; Initiation Expected in April of 2026 with Data Anticipated in the Fourth Quarter. $10.3 Million in Cash and Cash Equivalents at End of Year and Proceeds From January 2026 Public Offering is Expected to Fund the Company Into the Fourth Quarter of 2026. CAMBRIDGE, Mass., March 26, 2026 /PRNewswire/ -- MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2025, and provided a corporate strategic update.Mr. Kim continued, \"Beyond DA-1726, we continued to advance vanoglipel , a novel G-Protein-Coupled Receptor 119  agonist, with the presentation of positive Phase 2a data at the American Association for the Study of Liver Dis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OXM","BK4202","MTVA","PK","BK4218","BK4232","R","BK4181","BK4139","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004697","title":"ADVISORY-Alert wrongly tagged to Metavia Inc withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004697?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:05","pubTimestamp":1774469122,"startTime":"0","endTime":"0","summary":"ADVISORY-Alert wrongly tagged to Metavia Inc withdrawnAn alert on Meta's response on the Los Angeles verdict was inadvertently tagged to Metavia Inc MTVA.O, an unrelated entity, and has been withdrawn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D11I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620739613","title":"MetaVia Inc  expected to post a loss of $1.24 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620739613","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620739613?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:08","pubTimestamp":1774012087,"startTime":"0","endTime":"0","summary":"MetaVia Inc  expected to post a loss of $1.24 a share - Earnings Preview MetaVia Inc MTVA.OQ MTVA.O is expected to  show no change in quarterly revenue when it reports  results on March 23 (estimated)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4081AQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620057265","title":"BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2620057265","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620057265?lang=en_us&edition=fundamental","pubTime":"2026-03-19 01:49","pubTimestamp":1773856151,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi TechnologiesWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL6N4060ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSPR","FICO","OVID","SABS","XYZ","DUOL","ARES","KNX","LCID","ISRG","DOCU","TE","CRC","LNTH","GIS","SLG","MTVA","ABBV","STZ","WAL","HL","CDE","BMRA","APD","PTGX","RNXT","SAIL","ORA","LEN","SBUX","USEG","ARTL","CTMX","NEM","ARVN","GEMI","VRTX","SOFI","MMED","TTD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620549259","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2620549259","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620549259?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:11","pubTimestamp":1773839486,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, ProtagonistWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL6N4060JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STZ","NFLP","GEMI","NFXS","GEMG","MA","WAL","SBUX","NWMX","CRC","CDE","SABS","TTD","CCUP","ARTL","NBIL","OVID","DOCU","HL","AU","NEM","01698","SBU","MTVA","PTGX","IAUX","ARVN","ICRC","NEMG","NBIZ","TCHmain","NBIG","NFLW","BMRA","XYZ","SLG","FICO","SAIL","APD","NFLY","RNXT","CF","TE","NEBX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620517253","title":"BRIEF-Metavia Advances Glp-1-Based Obesity Program With Irb Approval For Higher-Dose Phase 1 Studies Of Da-1726, A Glp-1 And Glucagon Dual Agonist Demonstrating Best-In-Class Potential For Weight Loss And Glucose Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2620517253","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620517253?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:04","pubTimestamp":1773835469,"startTime":"0","endTime":"0","summary":"BRIEF-Metavia Advances Glp-1-Based Obesity Program With Irb Approval For Higher-Dose Phase 1 Studies Of Da-1726, A Glp-1 And Glucagon Dual Agonist Demonstrating Best-In-Class Potential For Weight Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4060PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253822","title":"MetaVia wins IRB approval for Phase 1 Part 3 trial of DA-1726 in obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253822","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253822?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:02","pubTimestamp":1773835321,"startTime":"0","endTime":"0","summary":"Metavia said an Institutional Review Board at Clinical Pharmacology of Miami approved its Phase 1 Part 3 trial of DA-1726, a GLP-1 and glucagon dual agonist. The trial plans to enroll 40 obese, otherwise healthy adults across two 16-week dose-titration cohorts. Part 3A will test 16 mg for 4 weeks followed by 48 mg for 12 weeks, while Part 3B will test 16 mg for 4 weeks followed by 32 mg for 4 weeks and 64 mg for 8 weeks.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire  on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL3h7Zqq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620258044","title":"Metavia Advances Glp-1-Based Obesity Program With Irb Approval for Higher-Dose Phase 1 Studies of Da-1726, a Glp-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2620258044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620258044?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:00","pubTimestamp":1773835206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4060PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619682824","title":"MetaVia Inc  expected to post a loss of $1.24 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619682824","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619682824?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:32","pubTimestamp":1773664342,"startTime":"0","endTime":"0","summary":"MetaVia Inc  expected to post a loss of $1.24 a share - Earnings Preview MetaVia Inc MTVA.OQ MTVA.O is expected to  show no change in quarterly revenue when it reports  results on March 18 (estimated)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL8N40413S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618132076","title":"MetaVia expands vanoglipel patent portfolio protection into 2035","url":"https://stock-news.laohu8.com/highlight/detail?id=2618132076","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618132076?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:04","pubTimestamp":1773320651,"startTime":"0","endTime":"0","summary":"MetaVia said its global intellectual property portfolio for vanoglipel includes 48 granted and pending patents across three patent families. The company said the patents cover the compound, manufacturing methods, and pharmaceutical compositions. MetaVia said the portfolio includes the U.S., Europe, Japan, China and other countries, with protection into 2035 unless extended further. President and CEO Hyung Heon Kim commented on the company’s intellectual property strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire  on March 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL2fnKnQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616553294","title":"MetaVia CEO Hyung Heon Kim to Join Life Sciences Virtual Investor Forum Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2616553294","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616553294?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:31","pubTimestamp":1772631085,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire  on March 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL1yLzjW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613754719","title":"MetaVia Inc. Publishes Investor Presentation on Obesity and MASH Drug Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2613754719","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613754719?lang=en_us&edition=fundamental","pubTime":"2026-02-24 09:26","pubTimestamp":1771896400,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL6cnPwp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612045013","title":"MetaVia Showcases Novel Obesity and Metabolic Therapies at Emerging Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612045013","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612045013?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:02","pubTimestamp":1771336968,"startTime":"0","endTime":"0","summary":"MetaVia Showcases Novel Obesity and Metabolic Therapies at Emerging Growth Conference               MetaVia Inc. (Nasdaq: MTVA) will present an update on its pipeline of novel obesity and metabolic th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL2ncPm8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611090162","title":"BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Mohawk,","url":"https://stock-news.laohu8.com/highlight/detail?id=2611090162","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611090162?lang=en_us&edition=fundamental","pubTime":"2026-02-14 02:35","pubTimestamp":1771007702,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Mohawk,Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refini.tv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nL6N3Z90O4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["H","FDX","BK4210","MTVA","LU0251142724.SGD","BK4505","PSA","HTGC","BK4534","IRD","IMUX","WYNN","ABNB","BK4114","DXCM","CDE","NEM","WTS","LU2764262908.HKD","CART","LU0498741890.SGD","LU0205193047.USD","CLF","MRNA","PINS","HL","MHK","EXPE","LU0130103400.USD","DKNG","LU0130102774.USD","WEN","AMKR","DLTR","IR","RYAN","NUE","LU1223083913.SGD","TOST","TPH","IE00B19Z3581.USD","CHRS","GB00BDT5M118.USD","ROKU","STLD","HK0000914660.USD","HWM","AAP","BIO"],"isVideo":false,"video":null,"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":49,"code":"91000000","status":"200"}]}}